TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04794127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Patients will be treated with Trabectedin administered at a dose of 1.5 mg/m2-1.3 mg/m2 (according to investigator's choice, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access every 3 weeks and pioglitazone given continuously at the daily dose of 45 mg by oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone Oral Product
Description: Patients will be treated with Trabectedin administered at a dose of 1.5 mg/m2-1.3 mg/m2 (according to investigator's choice, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access every 3 weeks and pioglitazone given continuously at the daily dose of 45 mg by oral route.
Study: NCT05794828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Injection
Description: Bucivacaine will be administered intramuscularly according to package insert directions after first numbing the area with lidocaine subcutaneously
Study: NCT06092866

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital triage
Description: A registered nurse assesses the symptoms reported by the patient on the online platform and gives appropriate advice for further care using chat.
Study: NCT06256042

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Occlusal splint
Description: a stabilizing maxillary acrylic occlusal splint was made, flat, total and adjusted in central relation (RC).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthrocentesis
Description: The patient then underwent arthrocentesis of the temporomandibular joint itself, following the Nitzan technique.
Study: NCT05040581

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1-Day CBT-Based Workshop for Preventing PPD
Description: The intervention is a 6-hour long CBT-based workshop. The intervention will be delivered in in modules and contain content on PPD etiology (with a focus on modifiable risk factors), the development of cognitive skills including cognitive restructuring, behavioural skills such as problem solving, sleep strategies, behavioural activation, assertiveness, and self-care, and the final module will involve goal setting and action planning.
Study: NCT05341700

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Impact Load Exercises
Description: Participants will complete 50-65 min running protocol on treadmill and 5 sets of 10 jumping exercises for 5 consecutive days. Participants will also be provided all meals and snacks to induce a energy-restricted state for the 5-day period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No Impact Load Exercises
Description: Participants will complete only a 50-65 min running protocol on treadmill for 5 consecutive days. Participants will also be provided all meals and snacks to induce a energy-restricted state for the 5-day period.
Study: NCT05376839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cedirogant
Description: Capsule, Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cedirogant
Description: Capsule, Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cedirogant
Description: Capsule, Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cedirogant
Description: Capsule, Oral
Study: NCT06063915

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Isoinertial training
Description: The subjects included in the study will undergo traditional muscle strengthening for a period of 4 weeks, with 2 sessions per week consisting of strength training using isoinertial machines
Study: NCT06136611

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TTFields
Description: TTFields will be delivered through 4 transducer arrays with 9 insulated electrodes each placed on the shaved scalp and connected to a portable device set to generate 200-kHz electric fields within the brain.
Study: NCT04823624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBG453
Description: intravenous infusion
Study: NCT04859374

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfullness
Description: Behavioral approach (mindfulness) delivered on line and smart phone for 6 weekly sessions

Intervention type: DRUG
Group type: OTHER
Intervention: treatment as usual (TAU) (pharmacological)
Description: Any pharmacological therapy used for managing chronic pain or chronic migraine

Intervention type: DRUG
Group type: OTHER
Intervention: treatment as usual (TAU) (pharmacological)
Description: Any pharmacological therapy used for managing chronic pain or chronic migraine
Study: NCT06186986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: 5 Participants will receive unlabeled brentuximab and 20 participants will receive 89ZR-Brentuximab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: 5 Participants will receive unlabeled brentuximab and 20 participants will receive 89ZR-Brentuximab.
Study: NCT06063915

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength Training
Description: The subjects included in the study will undergo traditional muscle strengthening for a period of 4 weeks, with 2 sessions per week consisting of strength training using classic exercises
Study: NCT06500403

Intervention type: DIAGNOSTIC_TEST
Intervention: liver and stiffness measurement
Description: liver and spleen stiffness measurement are non-invasive tools for evaluation of cirrhosis and portal hypertension
Study: NCT05861232

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral
Description: fear and anxiety during inhalation therapy
Study: NCT05537935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Naltrexone
Description: Subjects will be started with 3mg LDN orally administered daily for one week with a planned increase to 4 mg/day beginning week two, if tolerated. They will be provided a 4 week supply of study medication. The most common side effects are difficulty sleeping and vivid dreams, which is seen more frequently with nighttime dosing, so LDN will be given as a daytime dose.
Study: NCT04223674

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serological screen and treat
Description: Multi-antigen sero-diagnostic test for measurement of P. vivax antibodies in plasma from finger stick as a means to detect hypnozoite carriers for treatment
Study: NCT05636306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NoNO-42
Description: A single intravenous infusion weight-based dose of NoNO-42 administered over 10±1 minute

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A volume of 0.9% normal saline matching the volume required for a weight-based dosing of NoNO-42, administered as a single 10±1 minute intravenous infusion.
Study: NCT05614141

Intervention type: DEVICE
Intervention: Lokomat Augmented Performance Feedback
Description: All participants will exercise with Lokomat Augmented Performance Feedback for six weeks. Augmented Performance Feedback has different virtual reality games.

Intervention type: OTHER
Intervention: Conventional Physiotherapy
Description: Conventional physiotherapy includes stretching, strengthening, balance, coordination and walking exercises under the guidance of a physiotherapist.
Study: NCT05536544

Intervention type: OTHER
Group type: OTHER
Intervention: IBDMED
Description: The IBDMED program will be applied for 8 weeks and include education on MED diet and lifestyle components, focused on increasing and diversifying dietary fiber intake, reduction of ultra-processed food intake and promoting an active lifestyle. This intervention is digitally supported by an interactive website application and step trackers to monitor lifestyle parameters.

Intervention type: OTHER
Group type: OTHER
Intervention: IBDMED
Description: The IBDMED program will be applied for 8 weeks and include education on MED diet and lifestyle components, focused on increasing and diversifying dietary fiber intake, reduction of ultra-processed food intake and promoting an active lifestyle. This intervention is digitally supported by an interactive website application and step trackers to monitor lifestyle parameters.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Dietary counseling according to the local dietary guidelines for patients with IBD
Study: NCT05614141

Intervention type: OTHER
Intervention: Conventional Physiotherapy
Description: Conventional physiotherapy includes stretching, strengthening, balance, coordination and walking exercises under the guidance of a physiotherapist.
Study: NCT05536544

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Dietary counseling according to the local dietary guidelines for patients with IBD
Study: NCT05567848

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive Transcranial Magnetic Stimulation (rTMS)
Description: rTMS is a technique of TMS that allows the selective external manipulation of neural activity in a non-invasive manner. During TMS, a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field that in turn induces electrical current in neurons and allows the modulation of neural circuitry. The combination of TMS with functional MRI allows the selective targeting and modulation of brain networks. The repeated application of rTMS can cause long term changes in behavior and task performance that is reflected in altered brain network connectivity.~The pattern of rTMS will consist of intermittent Theta Burst Stimulation (iTBS) pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses per session. Sessions will be separated by an interval of 50 minutes (up to a total of 8 per day).
Study: NCT05459584

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Technological Rehabilitation
Description: Specific rehabilitation for balance disorder using the robotic platform
Study: NCT05648019

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD19 CAR T-cells
Description: A target per-protocol dose of vi able CD19 CAR transduced T-cells will consist of a single infusion of 0.2 to 5.0 x 10e6 lentiviral-transduced viable 41BB-CD19 CAR T-cells per kg body weight.
Study: NCT05714137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluation of the Effect of Proximal Massage and Fist Clenching in Reducing the Risk of Phlebitis From Peripheral Venous Catheter
Description: Proximal massage: For a total of 5 to 10 minutes, twice daily for 4 days, between 30 seconds- 1 minute in sessions of approximately 20 strokes, a light massage is administered utilizing the palm surfaces of the fingers.~Fist Clenching : Under the researcher's supervision, participants in the activity known as palm fisting squeeze a soft palm ball 20 times in each of 2 days a day for four days, lasting between 30 seconds - 1 minute.
Study: NCT00000829

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Vaccine, Polyvalent (23-valent)
Description: Administered as an injection at 24 months of age

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pneumococcal Vaccine, Polyvalent (23-valent)
Description: Administered as an injection at 24 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Conjugate Vaccine, Heptavalent
Description: Administered as an injection at 0, 2, 4, and 15 months of age

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered at 0, 2, 4, and 15 months of age
Study: NCT06195033

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical protocol guided by artificial intelligence software
Description: At present, the indications for internal fixation of intertrochanteric fractures are not clear. We developed an artificial intelligence software to assist surgeons in determining whether to immobilize lateral and medial posterior wall fractures.
Study: NCT05308420

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pericapsular nerve group (PENG) block
Description: A 22 gauge 120mm nerve block needle will be introduced under ultrasound guidance in plane from superolateral to posteromedial to position the needle tip posterolateral to the ileopsoas tendon in-between the anterior inferior iliac spine and the ileopubic (ileopectineal) eminence and 20ml 0.5% levobupivacaine with 2mg (0.5ml) dexamethasone injected (total volume of injectate 20.5ml) between the tendon and the inferior pubic ramus just proximal to the attachment of the anterior hip capsule

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia
Description: Spinal anesthesia will be performed at the level of the presumed interspace in-between the third and fourth lumbar vertebrae by introducing a 27 gauge pencil-point spinal needle and 15mg of levobupivacaine (3ml) injected intrathecally

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia
Description: Spinal anesthesia will be performed at the level of the presumed interspace in-between the third and fourth lumbar vertebrae by introducing a 27 gauge pencil-point spinal needle and 15mg of levobupivacaine (3ml) injected intrathecally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine
Description: 100 micrograms of preservative free morphine diluted to a volume of 0.5ml is added to the local anesthetic solution injected for spinal anesthesia (total injectate volume 3.5ml)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham PENG block
Description: A 22 gauge 120mm nerve block needle will be introduced under ultrasound guidance in plane from superolateral to posteromedial to position the needle tip posterolateral to the ileopsoas tendon in-between the anterior inferior iliac spine and the ileopubic (ileopectineal) eminence and a placebo solution consisting of 20.5ml 0.9%NaCl injected between the tendon and the inferior pubic ramus just proximal to the attachment of the anterior hip capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal placebo
Description: 0.5ml of placebo solution (0.9%NaCl) is added to the local anesthetic solution injected for spinal anesthesia (total injectate volume 3.5ml)
Study: NCT06008522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab-800CW
Description: Imaging of fluorescently labeled Bevacizumab-800CW using OCT.
Study: NCT05358158

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative air leak test
Description: A standard 28 Fr chest drain is inserted through the anterior port hole with all port holes closed. With the tip of the chest tube below water, the pleura is emptied from air during continuous ventilation of the lungs. An air leak after 5 minutes of ventilation indicates a negative sealing test, whereas a cessation of air leak within 5 minutes indicates a positive sealing test.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative air leak test
Description: A standard 28 Fr chest drain is inserted through the anterior port hole with all port holes closed. With the tip of the chest tube below water, the pleura is emptied from air during continuous ventilation of the lungs. An air leak after 5 minutes of ventilation indicates a negative sealing test, whereas a cessation of air leak within 5 minutes indicates a positive sealing test.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative chest drain removal
Description: Chest drain is removed intraoperatively.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard chest drain placement
Description: Chest drain is left in pleura.
Study: NCT04944121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RSLV-132
Description: 10 mg/kg RSLV-132 administered by intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9%
Description: 0.9% sodium chloride administered by intravenous infusion
Study: NCT04805606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-843 A
Description: Single Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-843 A
Description: Single Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-843 A
Description: Single Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-843 B
Description: Single Dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CKD-843-R
Description: QD, PO
Study: NCT06133595

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: MiBridge
Description: A series of five conversations over three weeks to help participants understand more about themselves and their willingness to change, and to help participants connect with the care they need and want.
Study: NCT06407141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: transcranial pulse stimulation
Description: Participants in the experimental arm will receive six sessions of Transcranial Pulse Stimulation (TPS) over a two-week period, using the NEUROLITH® TPS system (Storz Medical AG, Switzerland). Each session will involve delivering 6,000 ultrasound pulses at an energy level of 0.2-0.25 mJ/mm² and a frequency of 4-5 Hz, targeting specified brain regions based on MRI navigation.
Study: NCT05400993

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide: take orally twice a week,4 tablets/time (20mg/ time), the interval between two doses should not be less than 3 days (such as Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.), the day before chemotherapy, 30 minutes after breakfast； Chidamide: 20mg, orally, twice a week, oral for two weeks and one week, a total of 8 cycles； Epirubicin 90mg/m2 , ivgtt, d1 Cyclophosphamide 600mg/m 2, ivgtt, d1 Q3w, 4 cycle； sequential Docetaxel 100 mg/m 2, IVGtt, D1 Q3w, 4 cycle。
Study: NCT04806802

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APIOC Sphere and APIOC Astigmatism
Description: Single Vision Contact Lenses
Study: NCT04766112

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group I
Description: Group I will receive yang style Tai chi exercises combined with mental imagery training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group II
Description: Group II will receive yang style Tai chi exercise which consist of 10 positions.
Study: NCT05475860

Intervention type: DEVICE
Intervention: implantable cardiac electronic device recipients
Description: implantable cardiac electronic device recipients for any clinical indication
Study: NCT06407141

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham TMS
Description: Participants in the sham control group will undergo six sessions over a two-week period, utilizing the same NEUROLITH® TPS system (Storz Medical AG, Switzerland) as used in the experimental group. The key difference lies in the standoff device attached to the handpiece: while the experimental arm uses a standoff filled with silicone oil to transmit ultrasound pulses, the sham group\&#39;s standoff is filled with air. This design ensures that the sham device replicates the appearance, feel, and sound of the active treatment without transmitting any therapeutic pulses, effectively maintaining the blinding aspect of the study.
Study: NCT05242874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant, tropisetron, and olanzapine-based antiemetic regimen
Description: Fosaprepitant 150 mg intravenously on Day 1, tropisetron 5 mg intravenously on Day 1, and olanzapine 5 mg orally on Days 1 to 4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosaprepitant, tropisetron, olanzapine, and dexamethasone-based antiemetic regimen
Description: Fosaprepitant 150 mg intravenously on Day 1, tropisetron 5 mg intravenously on Day 1, and olanzapine 5 mg orally on Days 1 to 4. Dexamethasone 12 mg on Day 1, followed by 8 mg on Days 2 to 4.
Study: NCT06303245

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ABDOMINAL BINDERS
Description: will be given abdominal binders along with basic physiotherapy care. Physiotherapy care will include sitting exercises such as deep breathing exercises, protected huffing technique will be performed to improve gases exchange and remove secretion. In supine exercises such as basic ROM, ankle pumps, pelvic rolling, leg sliding will be performed. Each exercise will be of 10 repetition. This exercise will be given for 2 days per week for 6 weeks. Along with these exercises education related postural management and breastfeeding positions will also be guided

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: will receive TENS with high frequency (F=100Hz and T=100μs), intensity according to patient's pain threshold, duration of 30 continuous minutes, 2 cm above and below incision, with electrodes transversally positioned and crossing the incision. Two treatment sessions will be done per week for the period of 6 weeks. This group will be given tens along with abdominal binders with basic physiotherapy care. (23) In this treatment female's abdomen will be measured by a standard inch tape, then, according to the abdominal circumference, the binder will be fastened for 6 weeks. The binder will be placed tightly at the lower abdominal level with the incision positioned at the middle part of the binder. Participants will be asked to note the time to record the duration of binder wearing before taking the break. The binder will be opened between 10 pm and 8 am. This group will be given abdominal binders along with basic physiotherapy care
Study: NCT04872517

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Meridian Electroacupuncture Analysis Device (MEAD)
Description: use MEAD to detect energy change in patient with head and neck cancer
Study: NCT04724967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CeraVe Hydrating Cleanser
Description: topical cleanser applied twice a day for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CeraVe Moisturizing Cream
Description: topical cream applied twice a day for 28 days
Study: NCT06338202

Intervention type: DRUG
Intervention: Mavacamten
Description: As detailed in the product label
Study: NCT05791240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Initiated Interpretation
Description: Interpreter tablet will be given to families so they can contact an interpreter themselves.